Trial Profile

Phase 1 study of ACE910 in healthy volunteers and hemophilia A patients

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 12 Oct 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Emicizumab (Primary)
Indications Haemophilia A
Focus Adverse reactions; First in man; Pharmacodynamics; Pharmacokinetics
Sponsors Chugai Pharmaceutical

Most Recent Events

05 Jun 2020 Results (n=389) of a population pharmacokinetics and exploratory exposure analysis from six clinical studies: HAVEN1, HAVEN2, HAVEN3, HAVEN4, JapicCTI-121934 and JapicCTI-132195 published in the Clinical Pharmacokinetics
26 May 2016 Results (n=18) published in the New England Journal of Medicine
26 May 2016 Results of 18 patients with haemophilia A were published in a Chugai Pharmaceutical media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com